Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder
BACKGROUNDHypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress and interpersonal difficulty. It is the most prevalent female sexual health problem globally, affecting approximately 10% of women, but has limited treatment options. Melanocortin 4 receptor (MC4R) agonists have emerged as a promising therapy for women with HSDD, through unknown mechanisms. Studying the pathways involved is crucial for our understanding of normal and abnormal sexual behavior.METHODSUsing psychometric, functional neuroimaging, and hormonal analyses, we conducted a randomized, double-blinded, placebo-controlled, crossover clinical study to assess the effects of MC4R agonism compared with placebo on sexual brain processing in 31 premenopausal heterosexual women with HSDD.RESULTSMC4R agonism significantly increased sexual desire for up to 24 hours after administration compared with placebo. During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity and deactivated the secondary somatosensory cortex, specifically in response to visual erotic stimuli, compared with placebo. In addition, MC4R agonism enhanced functional connectivity between the amygdala and the insula during visual erotic stimuli compared with placebo.CONCLUSIONThese data suggest that MC4R agonism enhanced sexual brain processing by reducing self-consciousness, increasing sexual imagery, and sensitizing women with HSDD to erotic stimuli. These findings provide mechanistic insight into the action of MC4R agonism in sexual behavior and are relevant to the ongoing development of HSDD therapies and MC4R agonist development more widely.TRIAL REGISTRATIONClinicalTrials.gov NCT04179734.FUNDINGThis is an investigator-sponsored study funded by AMAG Pharmaceuticals Inc., the Medical Research Council (MRC) (MR/T006242/1), and the National Institute for Health Research (NIHR) (CS-2018-18-ST2-002 and RP-2014-05-001).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:132 |
|---|---|
| Enthalten in: |
The Journal of clinical investigation - 132(2022), 19 vom: 03. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thurston, Layla [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Endocrinology |
|---|
| Anmerkungen: |
Date Completed 04.10.2022 Date Revised 07.10.2022 published: Electronic ClinicalTrials.gov: NCT04179734 Citation Status MEDLINE |
|---|
| doi: |
10.1172/JCI152341 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347052819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347052819 | ||
| 003 | DE-627 | ||
| 005 | 20231226032916.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1172/JCI152341 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1156.xml |
| 035 | |a (DE-627)NLM347052819 | ||
| 035 | |a (NLM)36189794 | ||
| 035 | |a (PII)e152341 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thurston, Layla |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2022 | ||
| 500 | |a Date Revised 07.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04179734 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUNDHypoactive sexual desire disorder (HSDD) is characterized by a persistent deficiency of sexual fantasies and desire for sexual activity, causing marked distress and interpersonal difficulty. It is the most prevalent female sexual health problem globally, affecting approximately 10% of women, but has limited treatment options. Melanocortin 4 receptor (MC4R) agonists have emerged as a promising therapy for women with HSDD, through unknown mechanisms. Studying the pathways involved is crucial for our understanding of normal and abnormal sexual behavior.METHODSUsing psychometric, functional neuroimaging, and hormonal analyses, we conducted a randomized, double-blinded, placebo-controlled, crossover clinical study to assess the effects of MC4R agonism compared with placebo on sexual brain processing in 31 premenopausal heterosexual women with HSDD.RESULTSMC4R agonism significantly increased sexual desire for up to 24 hours after administration compared with placebo. During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity and deactivated the secondary somatosensory cortex, specifically in response to visual erotic stimuli, compared with placebo. In addition, MC4R agonism enhanced functional connectivity between the amygdala and the insula during visual erotic stimuli compared with placebo.CONCLUSIONThese data suggest that MC4R agonism enhanced sexual brain processing by reducing self-consciousness, increasing sexual imagery, and sensitizing women with HSDD to erotic stimuli. These findings provide mechanistic insight into the action of MC4R agonism in sexual behavior and are relevant to the ongoing development of HSDD therapies and MC4R agonist development more widely.TRIAL REGISTRATIONClinicalTrials.gov NCT04179734.FUNDINGThis is an investigator-sponsored study funded by AMAG Pharmaceuticals Inc., the Medical Research Council (MRC) (MR/T006242/1), and the National Institute for Health Research (NIHR) (CS-2018-18-ST2-002 and RP-2014-05-001) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Endocrinology | |
| 650 | 4 | |a Melanocortin | |
| 650 | 4 | |a Neuroimaging | |
| 650 | 7 | |a Interleukin-1 Receptor-Like 1 Protein |2 NLM | |
| 650 | 7 | |a Receptor, Melanocortin, Type 4 |2 NLM | |
| 700 | 1 | |a Hunjan, Tia |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edouard G |e verfasserin |4 aut | |
| 700 | 1 | |a Wall, Matthew B |e verfasserin |4 aut | |
| 700 | 1 | |a Ertl, Natalie |e verfasserin |4 aut | |
| 700 | 1 | |a Phylactou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Muzi, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Bijal |e verfasserin |4 aut | |
| 700 | 1 | |a Alexander, Emma C |e verfasserin |4 aut | |
| 700 | 1 | |a Suladze, Sofiya |e verfasserin |4 aut | |
| 700 | 1 | |a Modi, Manish |e verfasserin |4 aut | |
| 700 | 1 | |a Eng, Pei C |e verfasserin |4 aut | |
| 700 | 1 | |a Bassett, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Abbara, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Goldmeier, David |e verfasserin |4 aut | |
| 700 | 1 | |a Comninos, Alexander N |e verfasserin |4 aut | |
| 700 | 1 | |a Dhillo, Waljit S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical investigation |d 1924 |g 132(2022), 19 vom: 03. Okt. |w (DE-627)NLM000005487 |x 1558-8238 |7 nnns |
| 773 | 1 | 8 | |g volume:132 |g year:2022 |g number:19 |g day:03 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1172/JCI152341 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 132 |j 2022 |e 19 |b 03 |c 10 | ||